RYBOX — Biotechnology Fund
Data updated: 2026-08-28
RYBOX — Biotechnology Fund. United States Multi-Cap / All-Cap Blend / Core Health Care Equity · $136.81M AUM. Holdings, fees, performance and SEC filings.
RYBOX Fund Overview
RYBOX — Biotechnology Fund is a US mutual fund managed by Rydex Series Funds, categorised as United States Multi-Cap / All-Cap Blend / Core Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US mutual fund
- Manager: Rydex Series Funds
- Category: United States Multi-Cap / All-Cap Blend / Core Health Care Equity
- Assets under management: $136.81M
- 1-year return: 58.0%
- Ticker: RYBOX
- SEC CIK: 0000899148
- SEC series ID: S000003802
- Share class ID: C000010596
RYBOX Holdings
Top 10 holdings of Biotechnology Fund by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Abbvie, Inc. | 8.17% |
| Amgen, Inc. | 5.05% |
| Gilead Sciences, Inc. | 4.49% |
| Vertex Pharmaceuticals, Inc. | 4.32% |
| Regeneron Pharmaceuticals, Inc. | 2.93% |
| Revolution Medicines, Inc. | 2.48% |
| Alnylam Pharmaceuticals, Inc. | 2.36% |
| Beone Medicines Ltd. | 2.17% |
| Moderna, Inc. | 2.15% |
| Biogen, Inc. | 2.13% |
RYBOX Portfolio Allocation
Asset-class allocation of Biotechnology Fund by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 99.6% |
| Cash & Equivalents | 1.2% |
RYBOX Performance
Total returns for RYBOX (as of 2026-09-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 19.2% |
| 1 year | 58.0% |
| 3 years (annualised) | 18.5% |
| 5 years (annualised) | 5.8% |
RYBOX Risk Information
Risk metrics for RYBOX, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 14.0%
RYBOX Costs and Fees
RYBOX costs about $165 per $10,000 invested per year in fund expenses.
- Net expense ratio: 1.65%
- Gross expense ratio: 1.68%
- Portfolio turnover: 51%
- Brokerage commissions: 2.49 bps of average net assets (SEC N-CEN)
RYBOX Cashflows
Over the 12 months to 2026-06, Biotechnology Fund had net inflows of $19.61M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-06 | $9.27M |
| 2026-05 | $1.99M |
| 2026-04 | −$28.08M |
| 2026-03 | −$189.18K |
| 2026-02 | −$772.29K |
| 2026-01 | $24.75M |
RYBOX Debt Constituents
No individual debt constituents are reported in Biotechnology Fund's latest SEC N-PORT filing.
RYBOX Prospectus and SEC Filings
Official Biotechnology Fund filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
- Prospectus (485BPOS) — filed 2024-07-29
- Prospectus (485BPOS) — filed 2023-07-31
- Prospectus (485BPOS) — filed 2022-07-29
- Portfolio holdings (N-PORT) — filed 2026-08-28
- Portfolio holdings (N-PORT) — filed 2026-06-01
- Portfolio holdings (N-PORT) — filed 2026-03-02
- Annual census (N-CEN) — filed 2026-06-15
- Annual census (N-CEN) — filed 2025-06-13
Related Funds
Other United States Multi-Cap / All-Cap Blend / Core Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.